FindTrial
Sign In

Comparison of in vitro efficacy of ozenoxacin vs mupirocin vs fusidic acid against gram positive organism

A comparative study of in vitro efficacy of ozenoxacin vs mupirocin vs fusidic acid against gram positive clinical isolates

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/09/045794
Enrollment
150
Registered
2022-09-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: ozenoxacin broth: MIC calculation(MIC 50, MIC90 Control Intervention1: Fusidic acid: Mic calculation, MIC50, MIC90 Control Intervention2: Mupirocin: MIC calculation MIC 50, MIC 90

Sponsors

SIKSHA O ANUSANDHAN university
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients more than 2 months of age with pyoderma

Exclusion criteria

Exclusion criteria: 1. Pregnancy and lactation

Design outcomes

Primary

MeasureTime frame
The identification and sensitivity pattern will be performed by Vitek 2, Biomerieux. MIC will be performed by micro broth dilution technique for ozenoxacin, mupirocin and fusidic aciTimepoint: Baseline and after 5 days—

Secondary

MeasureTime frame
Susceptibility will be determined using breakpoints set by the CLSI for ozenoxacin and that British Society for Antimicrobial Chemotherapy (BSAC) breakpoints will be used for fusidic acid and mupirocin against staphylococci . Standard statistical methods will be used to calculate MIC50 and MIC90.Timepoint: Baseline, after 5 days—

Countries

India

Contacts

Public ContactDr Nibedita Dixit

Ims and Sum Hospital

nibeditadixit@soa.ac.in8249855790

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026